University of Pittsburgh-ko ikertzaileekin lankidetzan egindako argitalpenak (8)

2024

  1. Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 3

2019

  1. Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

    Cell, Vol. 176, Núm. 1-2, pp. 334-347.e12

  2. Metabolic consequences of T-cell costimulation in anticancer immunity

    Cancer Immunology Research, Vol. 7, Núm. 10, pp. 1664-1669

2018

  1. Perspectives in immunotherapy: Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

    Journal for ImmunoTherapy of Cancer, Vol. 6, Núm. 1

2016

  1. Emerging opportunities and challenges in cancer immunotherapy

    Clinical Cancer Research, Vol. 22, Núm. 8, pp. 1845-1855

2015

  1. Consensus nomenclature for CD8+ T cell phenotypes in cancer

    OncoImmunology, Vol. 4, Núm. 4

  2. Future perspectives in melanoma research: Meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014

    Journal of Translational Medicine, Vol. 13, Núm. 1

2014

  1. Classification of current anticancer immunotherapies

    Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508